When was CG Oncology founded?

CG Oncology was founded in 2010 and raised its 1st funding round 4 years after it was founded.

Where is CG Oncology located?

CG Oncology is headquartered in Irvine, United States. It is registered at 400 Spectrum Center Drive Suite #2040 Irvine, CA 92618.

How many employees does CG Oncology have?

As of Aug 31, 2026, the latest employee count at CG Oncology is 202.

Is CG Oncology a funded company?

CG Oncology is a funded company, having raised a total of $318M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 30, 2014.

When was the latest funding round of CG Oncology?

CG Oncology's latest funding was a $***** Series E round on Aug 01, 2023, with participation from 10 investors.

Where does CG Oncology rank among its competitors?

CG Oncology ranks 60th amongst 3472 active competitors, of which 1156 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of CG Oncology?

CG Oncology's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

CG Oncology - 2026 Company Profile, Team, Funding, Competitors & Financials

CG Oncology is a public company based in Irvine (United States), founded in 2010. It operates as a Developer of immunotherapeutic agents for treating cancer. CG Oncology has raised $318M in funding from investors like ORI Capital, Longitude Capital and Decheng Capital. The company has 3472 active competitors, including 1156 funded and 809 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

GC Oncology develops immunotherapeutic agents for treating cancer. The agents CG0070 is a modified adenovirus type 5 (Ad5) carrying an E2F-1 promoter upstream of an E1A promoter, and the gene for GM-CSF. The modification enables the virus to selectively target and replicate in cancer cells. The T cells are then able to circulate throughout the body, recognizing and attacking residual cancer.

Website: cgoncology.com
Social
Email ID: *****@cgoncology.com
Registered Address: 400 Spectrum Center Drive Suite #2040 Irvine, CA 92618

Key Metrics

Founded Year

2010

Location

Irvine, United States

Stage

Public

Total Funding

$318M in 6 rounds

Latest Funding Round

Series E, Aug 01, 2023, $*****

Investors

ORI Capital & 17 more

Ranked

60^th among 3472 active competitors

Employee Count

202 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3175 more

Exit Details

Public

View CG Oncology's full profile

CG Oncology is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Cg Oncology, Inc. CIN: - , United States, Active	Nov 29, 2017	-	-	-

CG Oncology got listed on Jan 25, 2024.

Click here to take a look at CG Oncology's IPO in detail

CG Oncology has raised a total funding of $318M over 6 rounds. Its first funding round was on Jul 30, 2014. Its latest funding round was a Series E round on Aug 01, 2023 for $*****. 10 investors participated in its latest round. CG Oncology has 18 institutional investors.

Here is the list of recent funding rounds of CG Oncology:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 01, 2023	5329270	Series E	8366219	1888228	7983366	5016490
Nov 15, 2022	4803884	Series E	1104296	5889521	8515711	RA Capital Management & 3 more
Dec 10, 2020	1636109	Series D	8106532	7955429	Kissei Pharmaceutical	ORI Capital & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of CG Oncology's funding rounds and investors

CG Oncology's employee count trend

CG Oncology has 202 employees as of Aug 26. Here is CG Oncology's employee count trend over the years:

Uncover CG Oncology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CG Oncology include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of CG Oncology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
60th	CG Oncology 2010, Irvine (United States), Public	Developer of immunotherapeutic agents for treating cancer	$318M	BVF Partners, Foresite Capital & 16 others	64/100